Document is current
Any future updates will be listed below
-
Authors
Michailidou, Iliana
Jongejan, Aldo
Vreijling, Jeroen P.
Georgakopoulou, Theodosia
de Wissel, Marit B.
Wolterman, Ruud A.
Ruizendaal, Patrick
Klar-Mohamad, Ngaisah
Grootemaat, Anita E.
Picavet, Daisy I.
Kumar, Vinod
van Kooten, Cees
Woodruff, Trent M.
Morgan, B. Paul
van der Wel, Nicole N.
Ramaglia, Valeria
Fluiter, Kees
Baas, Frank
-
Funding
Funding for this research was provided by:
National Multiple Sclerosis Society (RG 4775A1/1)
- License Information
-
More Information
Article History
Received: 30 March 2018
Accepted: 16 April 2018
First Online: 3 May 2018
Ethics approval
: All experiments were approved by the Academic Medical Center Animal Ethics Committee and complied with the Dutch national policy on humane care and the use of laboratory animals.
: FB, KF and VR are the inventors of patents that describe the use of inhibitors of the terminal complement pathway for therapeutic purposes; they are co-founders of Regenesance BV. FB. is founder of Complement Pharma BV.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
